Search Within

Ariela Noy

Formats
  1. Meeting Abstract (204)
  2. Journal Article (143)
  3. Research Letter (10)
  4. Book Section (6)
  5. Review (6)
  6. Editorial (2)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (373)
  2. Department of Medicine (373)
  3. Hematologic Malignancies, Division of (373)
  4. Lymphoma (373)
  5. Survivorship Research (163)
  6. Population Sciences Research Program (150)

More Groups

People
  1. Andrew Zelenetz (187)
  2. Paul Hamlin (144)
  3. David Straus (139)
  4. Steven Horwitz (138)
  5. Maria Palomba (131)
  6. Alison Moskowitz (118)

More People

Years
  1. 2025 (9)
  2. 2024 (27)
  3. 2023 (24)
  4. 2022 (15)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (166)
  2. Journal of Clinical Oncology (42)
  3. Hematological Oncology (19)
  4. Leukemia and Lymphoma (15)
  5. Blood Advances (13)
  6. Annals of Oncology (12)

More Publications

Publishers
  1. American Society of Hematology (179)
  2. American Society of Clinical Oncology (43)
  3. Wiley Blackwell (23)
  4. Elsevier Inc. (21)
  5. Taylor & Francis Group (15)
  6. Ferrata Storti Foundation (12)

More Publishers

Results (373)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
    Journal Article

    Shyamsundar, S.; Pierson, S. K.; Connolly, C. M.; Teles, M.; Segev, D. L.; Werbel, W. A.; van Rhee, F.; Casper, C.; Brandstadter, J. D.; Noy, A.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save